1[1]Packer M.The neurohumoral hypothesia theory to explain the mechanism of disease progression in heart failure.J An Coll Cardiol.1992,20:248～254.
2[2]Hunt SA,Baker DW,Chin MH,et al.ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult:executive summary.A report of the ACC/AHA task force on practice guidelines.J Am Coll Cardiol,2001,35:2101～2113.
6[6]MERIT HF Study Group.Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Trial in Congestive Heart Failure (MERIT HF).Lancet.1999,353:2001～2007.
7[7]Wagstein F,Bristow MR.Beneficial effect of metoprolol in-idiopathic cardioaypathy.Lancet.1993,342(8885):1441～1446..
8[8]Lechat PP,Packer M,Chalon S,et al.Clinical effects of β-adrenergic blockage in chronic heart failure:a meta-analysis of double-blind,place-bo-controlled randomized trials.circulation,1998,98:1184～1191.
9[9]CIBIS II Investigators and Committees:The Cardiac Insufficiency Bisoprolol Study II(CIBIS II):a randomized trial.Lancet,1999,353(9146):9～13.
10[10]Packer M,Coats AJ,Fowler MB,et al.Effects of Carvedilol on survival in severe chronic heart failure.N Engl J Med,2001,344:1651～1658.
二级参考文献1
1Consensus recommendations for the management of chronic heart failure.On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure[].The American Journal of Cardiology.1999
2Charlap S, Lichstein E, William H, et al. Adrenergic blocking drug in the treatment of Congestive heart failure[ J]. Med Cli North Atn, 2001, 73(27) : 373.
3Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult : executive summary. A report of the ACC/AHA task force on practice guidelines[J]. J Am Coll Cardiol, 2001, 35: 2101-2113.
4Packer M. The neurohumoral hypothesia theory to explain the mechanism of disease progression in heart failure[J]. J Am Coll Cardiol, 1992, 20: 248-254.
6Australia-New Zealand Heart Failure Research Collaborative Group. Randomized, placebo-controlled trial of carvedilol with congestive heart failure due to ischemic heart disease[J]. Lancet, 1997, 349 (2) : 375-380.
7Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure[J]. N Engl J Med, 1996, 334(1) : 1349-1355.
8MERIT-HF Study Group. Effect of metoprolol CRPXL in chronic heart failure: Metoprolol CRPXL Randomised Intervention Trial in Congestive Heart Failure ( MERIT-HF ) [ J ]. Lancet, 1999, 353 (9169) : 2001-2007.
9CIBIS- Ⅱ Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study Ⅱ ( CIBIS-Ⅱ ) arandomised trial [ J]. Lancet, 1999, 353(1): 9-13.
